Anticoagulation in Atrial Fibrillation with Mixed Mitral Valve Disease

Introduction to Anticoagulation Guidelines

• The American College of Cardiology recommends warfarin for patients with moderate-to-severe mitral stenosis, as DOACs are contraindicated in this population 1, 2, 3
• The European Heart Journal guidelines state that patients with moderate-to-severe mitral stenosis should not receive DOACs due to increased thromboembolism and bleeding risk 4

Warfarin Dosing and Monitoring

• The American College of Cardiology recommends a target INR of 2.5 (range 2.0-3.0) for patients with moderate-to-severe mitral stenosis 6
• The Journal of the American College of Cardiology suggests starting warfarin at 2-5 mg daily and checking INR weekly during initiation, then monthly once stable in therapeutic range 1, 2, 7

DOAC Selection and Dosing

• The American College of Cardiology recommends apixaban 5 mg twice daily as a first-line treatment for patients with mild mitral stenosis or isolated mitral regurgitation 8
• The Circulation journal guidelines state that dabigatran 150 mg twice daily, rivaroxaban 20 mg once daily, and edoxaban 60 mg once daily are alternative DOAC options for patients with non-valvular AF 2

Risk Stratification and Anticoagulation Decisions

• The American College of Cardiology recommends calculating the CHA₂DS₂-VASc score to determine anticoagulation necessity, with a score ≥2 (men) or ≥3 (women) indicating mandatory anticoagulation 1, 2, 8
• The European Heart Journal guidelines state that patients with a CHA₂DS₂-VASc score of 1 (men) or 2 (women) should receive anticoagulation if they have other stroke risk factors 2, 5

Special Populations and Adjustments

• The Chest journal guidelines recommend using label-adjusted NOACs or dose-adjusted warfarin for patients with moderate CKD (CrCl 30-59 mL/min) 9
• The Journal of the American College of Cardiology suggests that patients with severe CKD (CrCl 15-30 mL/min) should receive rivaroxaban 15 mg once daily, apixaban 2.5 mg twice daily, or edoxaban 30 mg once daily 2, 7, 8

Monitoring Requirements

• The American College of Cardiology recommends monitoring INR weekly during warfarin initiation and monthly once stable in therapeutic range, with a target TTR >65-70% 1, 2, 9
• The Journal of the American College of Cardiology suggests monitoring renal and hepatic function annually for patients on warfarin or DOACs 7